Bank of New York Mellon’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $149M | Sell |
994,688
-396,499
| -29% | -$43.1M | 0.02% | 506 |
|
|
2026
Q1 | $129M | Buy |
1,391,187
+25,030
| +2% | +$2.51M | 0.02% | 535 |
|
|
2025
Q4 | $140M | Buy |
1,366,157
+413,106
| +43% | +$37M | 0.02% | 490 |
|
|
2025
Q3 | $59.5M | Buy |
953,051
+46,826
| +5% | +$2.55M | 0.01% | 912 |
|
|
2025
Q2 | $47.2M | Buy |
906,225
+54,173
| +6% | +$2.42M | 0.01% | 1035 |
|
|
2025
Q1 | $36.3M | Sell |
852,052
-47,850
| -5% | -$2.06M | 0.01% | 1156 |
|
|
2024
Q4 | $27.5M | Sell |
899,902
-49,309
| -5% | -$1.39M | 0.01% | 1373 |
|
|
2024
Q3 | $21.8M | Sell |
949,211
-331,010
| -26% | -$9.37M | ﹤0.01% | 1527 |
|
|
2024
Q2 | $37M | Buy |
1,280,221
+309,157
| +32% | +$7.2M | 0.01% | 1209 |
|
|
2024
Q1 | $20M | Sell |
971,064
-132,828
| -12% | -$2.85M | ﹤0.01% | 1571 |
|
|
2023
Q4 | $29.9M | Sell |
1,103,892
-58,204
| -5% | -$1.53M | 0.01% | 1380 |
|
|
2023
Q3 | $34.4M | Buy |
1,162,096
+688,726
| +145% | +$24.2M | 0.01% | 1221 |
|
|
2023
Q2 | $16.9M | Buy |
473,370
+104,277
| +28% | +$2.99M | ﹤0.01% | 1645 |
|
|
2023
Q1 | $8.65M | Sell |
369,093
-7
| -0% | -$200 | ﹤0.01% | 1999 |
|
|
2022
Q4 | $10M | Sell |
369,100
-19,941
| -5% | -$912K | ﹤0.01% | 1941 |
|
|
2022
Q3 | $20.9M | Buy |
389,041
+22,725
| +6% | +$1.17M | 0.01% | 1478 |
|
|
2022
Q2 | $14.8M | Buy |
366,316
+17,385
| +5% | +$861K | ﹤0.01% | 1710 |
|
|
2022
Q1 | $23.1M | Sell |
348,931
-823
| -0.2% | -$56.3K | ﹤0.01% | 1577 |
|
|
2021
Q4 | $35M | Buy |
349,754
+6,994
| +2% | +$723K | 0.01% | 1381 |
|
|
2021
Q3 | $42.8M | Buy |
342,760
+35,558
| +12% | +$4.22M | 0.01% | 1235 |
|
|
2021
Q2 | $38.2M | Buy |
307,202
+11,127
| +4% | +$1.5M | 0.01% | 1344 |
|
|
2021
Q1 | $45.2M | Sell |
296,075
-13,593
| -4% | -$2.05M | 0.01% | 1178 |
|
|
2020
Q4 | $39.9M | Buy |
309,668
+47,782
| +18% | +$5.5M | 0.01% | 1186 |
|
|
2020
Q3 | $29.3M | Buy |
261,886
+13,174
| +5% | +$1.21M | 0.01% | 1220 |
|
|
2020
Q2 | $20.2M | Buy |
248,712
+84,385
| +51% | +$6.8M | 0.01% | 1436 |
|
|
2020
Q1 | $11.4M | Buy |
164,327
+17,466
| +12% | +$1.34M | ﹤0.01% | 1625 |
|
|
2019
Q4 | $11.5M | Buy |
146,861
+13,884
| +10% | +$1M | ﹤0.01% | 1893 |
|
|
2019
Q3 | $8.49M | Buy |
132,977
+13,317
| +11% | +$1.17M | ﹤0.01% | 2012 |
|
|
2019
Q2 | $10.3M | Buy |
119,660
+61,125
| +104% | +$4.67M | ﹤0.01% | 1945 |
|
|
2019
Q1 | $4.49M | Buy |
58,535
+12,858
| +28% | +$713K | ﹤0.01% | 2381 |
|
|
2018
Q4 | $1.72M | Buy |
+45,677
| New | +$1.68M | ﹤0.01% | 2805 |
|
Other funds holding GH
EAM
EA
Bank of New York Mellon's GH Position: Q2 2026 in Review
Bank of New York Mellon reduced its Guardant Health (GH) stake by 29% in Q2 2026, selling an estimated $43.1M and leaving 994,688 shares worth $149M. The position accounts for 0.02% of the portfolio, ranked #506.
Bank of New York Mellon first reported a position in GH in Q4 2018 and has held it in 31 quarters since. 246 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- Bank of New York Mellon held 994,688 shares of Guardant Health worth $149M as of Q2 2026.
- Bank of New York Mellon sold 396,499 Guardant Health shares in Q2 2026, an estimated $43.1M.
- Guardant Health made up 0.02% of Bank of New York Mellon's portfolio in Q2 2026, its #506 holding.
- Bank of New York Mellon first reported a position in Guardant Health in Q4 2018 and has held it in 31 quarters since.
- 246 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.